| General information | |
| ACovPid: | ACoVP100385 |
| Trivial Name: | P4 |
| Amino Acids Sequence: | GINASVVNIQKEIDRLNEVAKNLNESLIDL |
| Length: | 30 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Source Description: | From the heptad repeat region 2 of spike protein of SARS-CoV |
| Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Inhibition Value Type: | IC50 |
| Inhibitory Effect: | 3.17 ± 0.24 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | Cell–cell fusion assay |
| Assay Description: | Our simple and convenient cell fusion inhibition assay can be used to screen and identify entry inhibitors of SARS-CoV. The requirement of trypsin treatment in this assay suggests that it mimics the entry from cell surface by direct fusion between viral and cell membranes. To examine the inhibitory effect of the peptides identified by the cell fusion inhibition assay on SARS-CoV, we carried out a previously described SARS-CoV infectivity assay for three HR1 peptides at the BSL-3 facility (PMID: 14519257, 15606632). Briefly, VeroE6 cells (1 × 10^4 cells, each well) prepared in 96-well were infected with 75 TCID50 of SARS-CoV TW01 strain, which were pre-incubated with or without different concentration of peptides in quadricates at 37 °C for 1 h. After incubation at 37 °C for 72 h, cytopathic effects were observed under light microscope, and the IC50 was determined. |
| Anti-CoV activity in vivo: | |
| Reference: | 18983873 |
| Comment: | |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | ACoVP100242 ACoVP100125 ACoVP100389 ACoVP100119 ACoVP100124 |